Revascularisation therapies improve the outcomes of ischemic stroke patients with atrial fibrillation and heart failure

Atrial fibrillation (AF) and heart failure (HF) carry a poor prognosis in acute ischaemic stroke (AIS). The impact of revascularisation therapies on outcomes in these patients is not fully understood.
Source: International Journal of Cardiology - Category: Cardiology Authors: Source Type: research

Related Links:

ConclusionsIn the treatment of AF, CA appeared to be superior to AADs, decreasing the risk of all-cause death and cardiovascular hospitalization and improving the long-term QoL of patients with AF. CA was better tolerated and more effective than pharmacological therapy and allowed for improved QoL.
Source: American Journal of Cardiovascular Drugs - Category: Cardiology Source Type: research
ConclusionsPostoperative implantation of a permanent RV pacemaker does not alter the long ‐term risks of HF and mortality following mitral valve surgery.
Source: Journal of Cardiac Surgery - Category: Cardiovascular & Thoracic Surgery Authors: Tags: ORIGINAL ARTICLE Source Type: research
AbstractAimsCardiomyopathies are a heterogeneous group of disorders that increase the risk for atrial fibrillation (AF). The aim of the study is to assess the prevalence of AF, anticoagulation management, and risk of stroke/transient ischaemic attack (TIA) in patients with cardiomyopathy.Methods and resultsThree thousand two hundred eight consecutive adult patients with cardiomyopathy (34.9% female; median age: 55.0  years) were prospectively enrolled as part of the EURObservational Research Programme Cardiomyopathy/Myocarditis Registry. At baseline, 903 (28.2%) patients had AF (29.4% dilated, 27.5% hypertrophic, 51.5...
Source: ESC Heart Failure - Category: Cardiology Authors: Tags: Original Research Article Source Type: research
AbstractAimsMajor bleeding events in heart failure (HF) patients are poorly described. We sought to investigate the importance of major bleeding and its impact on outcomes in HF patients.Methods and resultsWe analysed incident bleeding and ischaemic events during a 3  year follow‐up in 2910 HF outpatients included in a prospective multicentre registry. Major bleeding was defined as a Type ≥3 bleed using the Bleeding Academic Research Consortium definition. Ischaemic event was a composite of ischaemic stroke and myocardial infarction. Events were adjudicated by a blinded committee. At inclusion, most patients (89%...
Source: ESC Heart Failure - Category: Cardiology Authors: Tags: Original Research Article Source Type: research
CONCLUSIONS: Multimorbid patients with ACS are at a greater risk for worse outcomes than their nonmultimorbid counterparts. Lack of consistent measurement makes interpretation of the impact of multimorbidity challenging and emphasizes the need for more research on multimorbidity's effects on postdischarge healthcare utilization. PMID: 32925234 [PubMed - as supplied by publisher]
Source: The Journal of Cardiovascular Nursing - Category: Nursing Authors: Tags: J Cardiovasc Nurs Source Type: research
AbstractObjectivesThe OVID study will demonstrate whether prophylactic-dose enoxaparin improves survival and reduces hospitalizations in symptomatic ambulatory patients aged 50 or older diagnosed with COVID-19, a novel viral disease characterized by severe systemic, pulmonary, and vessel inflammation and coagulation activation.Trial designThe OVID study is conducted as a multicentre open-label superiority randomised controlled trial.ParticipantsInclusion Criteria1. Signed patient informed consent after being fully informed about the study ’s background.2. Patients aged 50 years or older with a positive test for SARS-...
Source: Trials - Category: Research Source Type: clinical trials
To determine the utility of the HAS-BLED (Hypertension, Abnormal renal/liver function, Stroke, Bleeding history or predisposition, Labile international normalized ratio, Elderly, Drugs/alcohol concomitantly) and CHA2DS2-VASc (Congestive heart failure, Hypertension, Age, Diabetes, previous Stroke/transient ischemic attack –VAScular disease) scores among patients on anticoagulation (AC) therapy for atrial fibrillation (AF) who have evidence of cerebral amyloid angiopathy (CAA).
Source: Mayo Clinic Proceedings - Category: Internal Medicine Authors: Tags: Original article Source Type: research
Hypertrophic cardiomyopathy (HCM) is a myocardial disease characterized by left ventricular hypertrophy not solely explainable by abnormal loading condition [1,2]. Patients with HCM show a different clinical course, ranging from an asymptomatic status, with no adverse events and normal or extended longevity, to a symptomatic condition in which several disease complications can occur [3]. Among HCM patients which experience disease progression, 3 different pathways have been identified: refractory heart failure (HF), requiring surgical myectomy/alcohol ablation (obstructive HCM, OHCM) or heart transplant (non-obstructive HC...
Source: International Journal of Cardiology - Category: Cardiology Authors: Tags: Editorial Source Type: research
Hypertrophic cardiomyopathy (HCM) is a myocardial disease characterized by left ventricular hypertrophy not solely explainable by abnormal loading condition [1,2]. Patients with HCM show a different clinical course, ranging from an asymptomatic status, with no adverse events and normal or extended longevity, to a symptomatic condition in which several disease complications can occur [3]. Among HCM patients which experience disease progression, 3 different pathways have been identified: refractory heart failure (HF), requiring surgical myectomy/alcohol ablation (obstructive HCM, OHCM) or heart transplant (non-obstructive HC...
Source: International Journal of Cardiology - Category: Cardiology Authors: Tags: Editorial Source Type: research
AF is the most common clinical arrhythmia that causes severe adverse cardiovascular events, such as ischaemic stroke and acute heart failure.1 Triggers from the pulmonary vein (PV) have been identified as crucial ectopic sources that initiate AF and pulmonary vein isolation (PVI) is the cornerstone for catheter ablation of AF.2,3 Per the European and US AF guidelines, catheter ablation of AF is currently recommended as the first-line therapy if anti-arrhythmic agents fail to mainta
Source: Radcliffe Cardiology - Category: Cardiology Authors: Source Type: research
More News: Atrial Fibrillation | Cardiology | Heart | Heart Failure | Ischemic Stroke | Stroke